Core Viewpoint - The company has approved the use of idle raised funds and self-owned funds for cash management, with a total limit of RMB 180 million, ensuring that it does not affect project construction or normal operations [1] Group 1: Cash Management Approval - The company and its subsidiaries are authorized to use up to RMB 30 million of idle raised funds and RMB 150 million of self-owned funds for cash management, effective for 12 months starting from March 9, 2025 [1] - Independent directors and the sponsor institution have expressed their agreement with the cash management proposal [1] Group 2: Investment Risk Analysis - The company plans to invest in structured deposit products, which are considered low-risk, but acknowledges potential market volatility affecting returns [2] - Risk control measures include timely analysis of cash management products and maintaining close contact with financial institutions to monitor fund operations [2][3] Group 3: Impact on Daily Operations - The use of idle self-owned funds for cash management is based on principles of risk prevention and prudent investment, ensuring the safety of the principal [5] - This approach is expected to enhance fund utilization efficiency and generate investment returns, ultimately benefiting the company and its shareholders [5] Group 4: Previous Cash Management Activities - As of August 1, 2025, the company has an outstanding balance of RMB 70 million in raised funds and RMB 920 million in self-owned funds invested in structured deposit products [6]
上海优宁维生物科技股份有限公司 关于使用闲置自有资金进行现金管理的进展公告